What is Regeneron Pharmaceuticals's evkeeza — revenue?

Regeneron Pharmaceuticals (REGN) reported evkeeza — revenue of $53.3M in Q2 2026.

What does evkeeza — revenue mean?

This metric represents the total net sales generated from the commercialization of a specific therapeutic product indicated for the treatment of rare genetic conditions, such as homozygous familial hypercholesterolemia. It reflects the market adoption, pricing strategy, and patient access success for this specialized pharmaceutical asset. Growth in this revenue stream indicates successful penetration into niche patient populations and the effective execution of the product's commercial lifecycle.

Regeneron Pharmaceuticals REGN Evkeeza — Revenue

Similar metrics at other companies

XER

XERSKeveyis — Product revenue, net

$11.89M+4.0%

OGNZetia — Revenue

$87M+2.4%

JAZZVyxeos — Revenue from Contract with Customer, Excluding Assessed Tax

$26.6M-9.8%

AMGNXGEVA — Total revenues

$411M-27.4%

LLYVerzenio — Revenue

$1.3B+12.3%

INVAZEVTERA — Revenue

$438K—

Other financials

Income statement

See full

Revenue$4.3B+16.7%

Operating income$1.3B+19.8%

Net income$1.3B-6.8%

EPS (diluted)$12.23-4.5%

Balance sheet

See full

Cash & equivalents$2.5B+22.3%

Total debt$2.7B+0.1%

Total equity$31.7B+5.9%

Total assets$41.7B+9.2%

Cash flow

See full

Operating cash flow$813.0M-29.0%

CapEx$240.2M+9.7%

Free cash flow$572.8M-38.1%

Valuation

See full

Market cap$72.88B+21.8%

Enterprise value$73.12B+20.8%

P/E16.8×+3.4×

P/S4.7×+0.5×

Profitability

See full

Gross margin94.9%—

Operating margin24.7%-2.3pp

Net margin27.9%-3.5pp

FCF margin24.2%-2.9pp

Returns & leverage

See full

Return on equity14%-1.3pp

Debt / equity0.1×0.0×

Current ratio3.3×-1.3×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's evkeeza — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regeneron Pharmaceuticals's evkeeza — revenue?: Regeneron Pharmaceuticals (REGN) reported evkeeza — revenue of $53.3M in Q2 2026.
What does evkeeza — revenue mean?: This metric represents the total net sales generated from the commercialization of a specific therapeutic product indicated for the treatment of rare genetic conditions, such as homozygous familial hypercholesterolemia. It reflects the market adoption, pricing strategy, and patient access success for this specialized pharmaceutical asset. Growth in this revenue stream indicates successful penetration into niche patient populations and the effective execution of the product's commercial lifecycle.